Does Dr. DENNIS BURACHINSKY have financial conflicts of interest?

Dr. DENNIS BURACHINSKY (D.O.) has received a total of $2,446 in pharmaceutical and medical device industry funding between 2021 and 2025. This includes $2,446 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. DENNIS BURACHINSKY?

According to CMS Open Payments data, Dr. DENNIS BURACHINSKY received funding from GENZYME CORPORATION ($646), OPTINOSE US ($449), and REGENERON HEALTHCARE SOLUTIONS ($280).

Does Dr. DENNIS BURACHINSKY receive research grants or speaking fees?

Dr. DENNIS BURACHINSKY has received $2,446 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. DENNIS BURACHINSKY

D.O.Real-Time Hydrated

Specialty: Otolaryngology, Otolaryngology/Facial Plastic Surgery

Practice Location: BRIDGEWATER, NJ 08807

NPI Number: 1427376698

LIFETIME INDUSTRY VALUE

$2,446

2021 – 2025 Cumulative

Conflict of Interest Analysis

Dr. BURACHINSKY is a verified Otolaryngology, Otolaryngology/Facial Plastic Surgery practitioner based in BRIDGEWATER, NJ.

Between 2021 and 2025, Dr. BURACHINSKY had an overall industry promotional and research financial footprint of $2,446 as recorded in the federal CMS Open Payments database.

$2,446 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. BURACHINSKY's primary funding source is GENZYME CORPORATION, which accounts for $646 (representing 26.4% of overall industry footprint).

Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

GENZYME CORPORATION

Rank 1

$646

26.4%

OPTINOSE US

Rank 2

$449

18.4%

REGENERON HEALTHCARE SOLUTIONS

Rank 3

$280

11.4%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2025

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.